SLE & Inflammation

Systemic Lupus Erythematosus (SLE, lupus) is a highly complex and heterogeneous autoimmune disease that most often afflicts women in their child-bearing years. It is characterized by circulating self-reactive antibodies that deposit in tissues including skin, kidneys and brain, and the ensuing infla…

Inflammation is the basis for repair and damage. Understanding the modes of inflammation in a particular disease holds the key to treating it specifically and effectively.
In SLE, practically every arm of the immune response plays a role in its pathogenesis. Predominance of certain modes of inflammation at different timepoints result in different sets of clinical manifestations. It also means that there will not be a single (or even a few) treatment that will treat every Lupus patient.
It’s complicated, very complicated. But there is no other way of getting a grip on this complicated disease, which has been called the Great Mimicker of diseases. Get ready for a rough ride.

Oxidized Mitochondrial DNA May Contribute to Inflammation in SLE

New research examines how the generation of reactive oxygen species and neutrophil extracellular traps may break down the protective mechanisms of…|By Lara C. Pullen, PhD

Casting a ‘NET’ to Find New Therapies for Lupus

Dr Deane discusses a study that first examined the role of neutrophil extracellular traps in lupus pathophysiology, and then evaluated metformin to reduce disease flares in a proof-of-concept trial.

Targeting Interferon Shows Promise in Lupus

Sifalimumab effective in a phase IIb trial, particularly for skin manifestations

Researchers Target Altered T Cell Metabolism in SLE to Reverse Lupus Immuno-Phenotype

A recent study on systemic lupus erythematosus examined the effects of metabolic modulators on the disease’s abnormal T cell metabolism. Using a combination…|By Lara C. Pullen, PhD

Study Reveals Role of IL-17–Secreting CD4+ T Cells in Lupus

Patients with systemic lupus erythematosus (SLE) are characterized by high-titer, highly specific, isotype-switched antibodies against DNA and RNA. Patients have…|By Lara C. Pullen, PhD

T Cells in Systemic Lupus Erythematosus

Progress toward targeted therapy

Regulatory B Cell Processes Appear Aberrant in Lupus

Disruption of the processes that govern the differentiation of immature B cells into regulatory B cells (Bregs) that restrain inflammation may contribute to the pathogenesis of systemic lupus erythematosus (SLE).